A Centre for Healthy Brain Ageing (CHeBA) paper published in Current Alzheimer Research presents the first detailed study of the relationship between plasma levels of two amyloid beta peptides (Aβ1-40 and Aβ1-42), brain volumetrics (measures studying the size of brain, which shrinks with Alzheimer’s disease) and cognitive performance in an investigation of the usefulness of plasma levels as a biomarker for Alzheimer’s disease (AD).
from Dementia Big http://ift.tt/1XFc3z0
via Stopping Dementia
from WordPress http://ift.tt/23VBVue
via alcoholic dementia
http://ift.tt/1SrQnbl
No comments:
Post a Comment